Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.35 USD

77.35
3,319,830

+0.48 (0.62%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (66 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

Astrazeneca (AZN) closed at $72.07 in the latest trading session, marking a -0.37% move from the prior day.

AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica

AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.

UnitedHealth (UNH) to Post Q1 Earnings: What You Should Expect

UnitedHealth's (UNH) first-quarter results are likely to reflect growing premiums and memberships.

The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer

J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates

J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.

The Zacks Analyst Blog Highlights Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup

Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Mastercard, AstraZeneca & Philip Morris

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AstraZeneca PLC (AZN) and Philip Morris International Inc. (PM).

AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal

Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.

Astrazeneca (AZN) Gains As Market Dips: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $70.25, moving +0.49% from the previous trading session.

Oncternal (ONCT) Down on Restructuring Plan to Extend Runway

Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.

AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease

CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

This is Why Astrazeneca (AZN) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.

Astrazeneca (AZN) Gains But Lags Market: What You Should Know

In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day.

Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study

Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.

Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Here's What is Driving Amgen (AMGN) Stock's Outperformance

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.

Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.

Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know

In the latest trading session, Astrazeneca (AZN) closed at $65.61, marking a -0.56% move from the previous day.

Astrazeneca (AZN) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.

AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?

AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.

Astrazeneca (AZN) Gains As Market Dips: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $65.18, moving +1.54% from the previous trading session.

AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies

Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.

Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi

J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.